Lmr Partners LLP Aurinia Pharmaceuticals Inc. Transaction History

Lmr Partners LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$4.11 - $8.14 $447,414 - $886,120	108,860 Added 385.25%	137,117 $592,000
Q3 2022 Nov 14, 2022	SELL	$6.66 - $12.39 $184,322 - $342,905	-27,676 Reduced 49.48%	28,257 $212,000
Q2 2022 Aug 15, 2022	BUY	$8.95 - $12.8 $500,600 - $715,942	55,933 New	55,933 $562,000
Q1 2022 May 16, 2022	SELL	$10.05 - $22.48 $860,209 - $1.92 Million	-85,593 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$17.78 - $33.08 $4.82 Million - $8.97 Million	-271,117 Reduced 76.0%	85,593 $1.96 Million
Q3 2021 Nov 15, 2021	BUY	$10.93 - $23.55 $3.9 Million - $8.4 Million	356,710 New	356,710 $7.89 Million
Q1 2021 May 17, 2021	SELL	$12.3 - $18.73 $782,685 - $1.19 Million	-63,633 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$11.34 - $21.46 $721,598 - $1.37 Million	63,633 New	63,633 $935,000

227

58.9M

949K

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.14B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Lmr Partners LLP with notifications on news.